Girard Partners’s Forte Biosciences FBRX Stock Holding History

Girard Partners’s Portfolio FBRX Stock Details FBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-3	Closed	-$15K	–	416
2018 Q3	$15K	Buy	+3	New	+$11.4K	﹤0.01%	653

Other funds holding FBRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

Girard Partners's FBRX Position: Q4 2018 in Review

Girard Partners sold out of Forte Biosciences (FBRX) in Q4 2018, closing a stake of 3 shares — an estimated $15K sold.

Girard Partners first reported a position in FBRX in Q3 2018 and held it in 1 quarter. The position peaked at $15K in Q3 2018. 80 funds tracked by Wall St. Rank hold FBRX as of Q4 2018.

Girard Partners reported no remaining Forte Biosciences position as of Q4 2018 after selling out during the quarter.
Girard Partners sold 3 Forte Biosciences shares in Q4 2018, an estimated $15K.
Girard Partners first reported a position in Forte Biosciences in Q3 2018 and held it in 1 quarter.
Girard Partners's Forte Biosciences position peaked at $15K in Q3 2018.
80 funds tracked by Wall St. Rank held Forte Biosciences as of Q4 2018.

Based on Girard Partners's 13F filing for Q4 2018, filed 11 Feb 2019.